RESUMO
Objective: To explore the protective effect of vitamin D in acute liver failure through a mouse model. Methods: Acute liver failure was induced by combining D-galactosamine (D-GalN) lipopolysaccharide (LPS) to observe the effect of long-term vitamin D deficiency on liver injury and inflammatory signals in a mouse model. Acute liver failure was induced by thioacetamide (TAA) to observe the effect of vitamin D deficiency on the survival rate, and further high-dose of vitamin D supplementation protective effect was determined in a mouse model. Liver function was evaluated by measuring serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and liver inflammation by hematoxylin-eosin staining. The expressions of tumor necrosis factor (TNF-α), interleukin (IL) -1ß, NOD-like receptor family, pyrin domain containing 3 (NLRP-3), chemokines (CCL2, CXCL1 and CXCL2), etc. in liver tissues were detected by RT-qPCR. The quantitation of macrophages in liver tissue was detected by immunohistochemistry. The comparison between groups were performed by t-test. The survival curve was analyzed by log-rank (Mantel-Cox) test. Results: Long-term vitamin D deficiency had increased acute liver failure sensitivity in mice, which was manifested by increased blood cell extravasation, massive necrosis of parenchymal cells, up-regulation of TNF-α, IL-1ß, and NLRP-3 mRNA expression (P < 0.05), and increased macrophages quantitation (P < 0.05) in liver tissues. At the same time, vitamin D deficiency had increased the mice mortality rate because of liver injury (P < 0.01). On the contrary, pre-administration of high dose of vitamin D (100 IU/g) had significantly reduced liver injury, inhibited ALT and AST rise (P < 0.01), alleviated liver necrosis, and down-regulated the mRNA expression of inflammatory factors in liver tissues (P < 0.05). Conclusion: Mouse model shows that long-term vitamin D deficiency can aggravate drug-induced acute liver failure and reduce survival rates. Furthermore, high-dose of vitamin D has a certain hepatoprotective effect, which can significantly improve liver necrosis condition and inhibit inflammation. Therefore, adequate vitamin D can retain liver physiological balance to resist liver injury.
Assuntos
Doença Hepática Induzida por Substâncias e Drogas , Falência Hepática Aguda , Vitamina D/uso terapêutico , Alanina Transaminase , Animais , Aspartato Aminotransferases , Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle , Galactosamina , Interleucina-1beta , Lipopolissacarídeos , Fígado , Falência Hepática Aguda/tratamento farmacológico , Falência Hepática Aguda/prevenção & controle , Camundongos , Proteína 3 que Contém Domínio de Pirina da Família NLR , Fator de Necrose Tumoral alfaRESUMO
ß-Hydroxybutyric acid (BHBA) has recently been shown to regulate hormone synthesis and secretion in the hypothalamus. However, little is known about the effects of BHBA-mediated hormone regulation or the detailed mechanisms by which BHBA regulates growth hormone-releasing hormone (GHRH) synthesis and secretion. In the present study, we examined the expression of the BHBA receptor GPR109A in primary hypothalamic cell cultures. We hypothesised that BHBA regulates GHRH via GPR109A and its downstream signals. Initial in vivo studies conducted in rats demonstrated that GHRH mRNA expression in the hypothalamus was strongly inversely correlated with BHBA levels in the cerebrospinal fluid during postnatal development (r = -0.89, P < 0.01). Furthermore, i.c.v. administration of BHBA acutely decreased GHRH mRNA expression in rats. Further in vitro studies revealed a decrease in GHRH synthesis and secretion in primary hypothalamic cells after treatment with BHBA; this effect was inhibited when hypothalamic cells were pretreated with pertussis toxin (PTX). BHBA had no effect on GHRH synthesis and secretion in GT1-7 cells, which do not exhibit cell surface expression of GPR109A. Furthermore, BHBA acutely decreased the transcription of the homeobox gene for Gsh-1 in the hypothalamus in both in vivo and in vitro, and this effect was also inhibited by PTX in vitro. In primary hypothalamic cells, BHBA activated the extracellular signal-regulated kinase (ERK)1/2, p38 and c-Jun N-terminal kinase mitogen-activated protein kinase (MAPK) kinases, as shown by western blot analysis. Moreover, inhibition of ERK1/2 with U0126 attenuated the BHBA-mediated reduction in Gsh-1 expression and GHRH synthesis and secretion. These results strongly suggest that BHBA directly regulates GHRH synthesis and secretion via the GPR109A/ERK1/2 MAPK pathway, and also that Gsh-1 is essential for this function.
Assuntos
Ácido 3-Hidroxibutírico/fisiologia , Hormônio Liberador de Hormônio do Crescimento/biossíntese , Hormônio Liberador de Hormônio do Crescimento/metabolismo , Hipotálamo/metabolismo , Receptores Acoplados a Proteínas G/biossíntese , Receptores Nicotínicos/biossíntese , Transdução de Sinais , Ácido 3-Hidroxibutírico/antagonistas & inibidores , Ácido 3-Hidroxibutírico/líquido cefalorraquidiano , Ácido 3-Hidroxibutírico/farmacologia , Animais , Butadienos/farmacologia , Células Cultivadas , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Feminino , Proteínas de Homeodomínio/biossíntese , Humanos , Proteína Quinase 1 Ativada por Mitógeno/antagonistas & inibidores , Proteína Quinase 3 Ativada por Mitógeno/antagonistas & inibidores , Nitrilas/farmacologia , Toxina Pertussis/farmacologia , Cultura Primária de Células , Ratos , Transdução de Sinais/efeitos dos fármacosRESUMO
Four new oleanane triterpenoid saponins named triplosides D-G were isolated from the roots of Triplostegia grandiflora. Their structures were elucidated on the basis of chemical degradation and spectral evidence. The saponins investigated were: oleanolic acid 3-O-beta-D-xylopyranosyl(1----4)-beta-D-xylopyranosyl(1----3)-beta-D- xylopyranosyl(1----4)-alpha-L-rhamnopyranosyl(1----3)-beta-D- xylopyranosyl(1----3)-alpha-L-rhamnopyranosyl(1----2)-beta-D-xylopyranos ide, oleanolic acid 3-O-beta-D-glucopyranosyl(1----6)-[beta-D- xylopyranosyl(1----4)]-beta-D-glucopyranosyl(1----3)-beta-D- xylopyranosyl(1----4)-alpha-L-rhamnopyranosyl(1----3)-beta-D- xylopyranosyl(1----3)-alpha-L-rhamnopyranosyl(1----2)-beta-D-xylopyranos ide, oleanolic acid 3-O-beta-D-xylopyranosyl(1----3)-beta-D-xylopyranosyl(1----4)- alpha-L-rhamnopyranosyl(1----3)-beta-D-xylopyranosyl(1----3)-alpha-L- rhamnopyranosyl(1----2)-beta-D-xylopyranoside and oleanolic acid 3-O-alpha-L-rhamnopyranosyl(1----3)-beta-D-xylopyranosyl(1---3)-alpha-L- rhamnopyranosyl(1----2)-beta-D-xylopyranoside, respectively. All of them have a common aglycone and are monodesmosides.